A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Chugai Pharmaceutical122 enrolled

Overview

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

122

Conditions

Chemotherapy Induced Anemia

Interventions

recombinant human erythropoietinDRUG

36000IU（0.5mL）s.c./week for 8 weeks

recombinant human erythropoietin placeboDRUG

0 IU(0.5mL)s.c./week for 8 weeks

Eligibility

Sex: ALLMin age: 20 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cancer patients Exclusion Criteria: * a history of myocardial, cerebral or pulmonary infarction * severe hypertension beyond control by drugs

Outcomes

Primary Outcomes

The increase in Hb concentration

Time frame: week 8

Secondary Outcomes

Changes in QOL scores

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.